Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1,4-benzenediol
2. 1,4-dihydroxybenzene
3. Artra
4. Beta-quinol
5. Eldopaque
6. Eldoquin
7. Esoterica
8. Hidroquilaude
9. Hidroquin
10. Hidroquinona Isdin
11. Hydroquinone, Copper (1+) Salt
12. Hydroquinone, Lead (2+) Salt (2:1)
13. Hydroquinone, Monocopper (2+) Salt
14. Licostrata
15. Lustra
16. Melanasa
17. Melanex
18. Melpaque
19. Melquin
20. Neostrata Hq
21. P-benzenediol
22. Phiaquin
23. Solaquin
24. Ultraquin
1. Benzene-1,4-diol
2. 1,4-benzenediol
3. 123-31-9
4. Quinol
5. 1,4-dihydroxybenzene
6. P-benzenediol
7. P-hydroquinone
8. P-hydroxyphenol
9. 4-hydroxyphenol
10. P-dihydroxybenzene
11. Benzoquinol
12. Eldoquin
13. Hydroquinol
14. Eldopaque
15. Phiaquin
16. P-dioxybenzene
17. Solaquin Forte
18. Dihydroquinone
19. Hydroquinole
20. Idrochinone
21. Tecquinol
22. Benzohydroquinone
23. Arctuvin
24. Hidroquinone
25. Tequinol
26. Dihydroxybenzene
27. Eldopaque Forte
28. Eldoquin Forte
29. Derma-blanch
30. Tenox Hq
31. Hydrochinon
32. Hydrochinone
33. Artra
34. Diak 5
35. Benzene, P-dihydroxy-
36. 1,4-dihydroxy-benzol
37. Usaf Ek-356
38. 1,4-diidrobenzene
39. Nci-c55834
40. P-dioxobenzene
41. 1,4-dihydroxybenzen
42. Black And White Bleaching Cream
43. Para-dioxybenzene
44. Para-hydroquinone
45. Pyrogentistic Acid
46. 1,4-dihydroxy-benzeen
47. He 5
48. Para-dihydroxybenzene
49. Melanex
50. Idrochinone [italian]
51. Hydrochinon [czech, Polish]
52. 1,4-dihydroxybenzen [czech]
53. 1,4-diidrobenzene [italian]
54. 1,4-dihydroxy-benzeen [dutch]
55. 1,4-dihydroxy-benzol [german]
56. Chebi:17594
57. Nsc 9247
58. Un2662
59. Hydroquinone [usp]
60. Ai3-00072
61. Nsc-9247
62. Mfcd00002339
63. Hq
64. Chembl537
65. Xv74c1n1ae
66. 1,4-benzenediol, Homopolymer
67. Dtxsid7020716
68. Hydroquinone [un2662] [poison]
69. Hydroquinone (usp)
70. Ncgc00015523-02
71. Beta-quinol
72. Dsstox_cid_716
73. Para-hydroxyphenol
74. Dsstox_rid_75754
75. Dsstox_gsid_20716
76. Eldopacque
77. Hydroquinone (benzene-1,4-diol)
78. Epiquin
79. Sunvanish
80. P Benzendiol
81. P-dihydroquinone
82. Alpha-hydroquinone
83. 26982-52-5
84. Cas-123-31-9
85. Smr000059154
86. Ccris 714
87. 1,4-hydroxybenzene
88. Hsdb 577
89. Sr-01000075920
90. 4-dihydroxybenzene
91. Einecs 204-617-8
92. Unii-xv74c1n1ae
93. Hydroquinon
94. Hydroquinoue
95. Hydroq Uinone
96. Hydroquinone Gr
97. A-hydroquinone
98. Black & White Bleaching Cream
99. P-hydroxybenzene
100. B-quinol
101. 4-benzenediol
102. Hydroquinone, Hq
103. .beta.-quinol
104. 1,4 Benzenediol
105. Hydroquinone,(s)
106. P-dihydroxy Benzene
107. Hqe
108. Hydroquinone Polymer
109. Plq
110. Artra (salt/mix)
111. 1, 4-benzenediol
112. Hydrop
113. .alpha.-hydroquinone
114. Phenol Derivative, 4
115. 4-hydroxyphenyl Alcohol
116. Spectrum_001757
117. 4e3h
118. Specplus_000769
119. 1,4-dihydrobenzoquinone
120. Eldoquin (tn)
121. Hydroquinone For Synthesis
122. Spectrum2_001672
123. Spectrum3_000656
124. Spectrum4_000633
125. Spectrum5_001430
126. Hydroquinone [mi]
127. Lopac-h-9003
128. Wln: Qr Dq
129. Bmse000293
130. Epitope Id:116206
131. Ec 204-617-8
132. Hydroquinone [hsdb]
133. Hydroquinone [iarc]
134. Hydroquinone [inci]
135. Hydroquinone [vandf]
136. 1,4-dihydroxybenzene Quinol
137. Lopac0_000577
138. Schembl15516
139. Bspbio_002291
140. Hydroquinone [mart.]
141. Kbiogr_001246
142. Kbioss_002237
143. 1,4-dihydroxybenzene, Xiii
144. Mls000069815
145. Mls001074911
146. Bidd:er0340
147. Divk1c_006865
148. Hydroquinone [usp-rs]
149. Hydroquinone [who-dd]
150. Hydroquinone, Lr, >=99%
151. Spectrum1504237
152. Hydrochinon(czech, Polish)
153. Spbio_001883
154. Bdbm26190
155. Hydroquinone, Puriss., 99.0%
156. Kbio1_001809
157. Kbio2_002237
158. Kbio2_004805
159. Kbio2_007373
160. Kbio3_001511
161. Nsc9247
162. Benzene-1,4-diol (hydroquinone)
163. Hms1922h15
164. Hms2093e08
165. Hms3261d16
166. Hydroquinone [orange Book]
167. Pharmakon1600-01504237
168. Hy-b0951
169. Zinc5133378
170. Hydroquinone [usp Monograph]
171. Tox21_110169
172. Tox21_202345
173. Tox21_300015
174. Tox21_500577
175. Ccg-39082
176. Nsc758707
177. S4580
178. Stk397446
179. Akos000119003
180. Tox21_110169_1
181. Tri-luma Component Hydroquinone
182. Am10548
183. Db09526
184. Lp00577
185. Nsc-758707
186. Sdccgsbi-0050559.p003
187. Un 2662
188. Hydroquinone 100 Microg/ml In Methanol
189. Hydroquinone, Reagentplus(r), >=99%
190. Hydroquinone, Usp, 99.0-100.5%
191. Ncgc00015523-01
192. Ncgc00015523-03
193. Ncgc00015523-04
194. Ncgc00015523-05
195. Ncgc00015523-06
196. Ncgc00015523-07
197. Ncgc00015523-08
198. Ncgc00015523-09
199. Ncgc00015523-10
200. Ncgc00015523-11
201. Ncgc00015523-12
202. Ncgc00015523-13
203. Ncgc00015523-19
204. Ncgc00090880-01
205. Ncgc00090880-02
206. Ncgc00090880-03
207. Ncgc00090880-04
208. Ncgc00090880-05
209. Ncgc00254037-01
210. Ncgc00259894-01
211. Ncgc00261262-01
212. Bp-21160
213. Da-33570
214. Hydroquinone Component Of Tri-luma
215. Hydroquinone, Reagentplus(r), >=99.5%
216. Sbi-0050559.p002
217. Hydroquinone, Saj First Grade, >=99.0%
218. Eu-0100577
219. Ft-0606877
220. H0186
221. Hydroquinone, Saj Special Grade, >=99.0%
222. Hydroquinone, Meets Usp Testing Specifications
223. C00530
224. D00073
225. H 9003
226. Ab00053361_08
227. Quinol; 1,4-benzenediol; 1,4-dihydroxybenzene
228. Q419164
229. Butylhydroxyanisole Impurity A [ep Impurity]
230. J-004910
231. J-521469
232. Sr-01000075920-1
233. Sr-01000075920-4
234. Q27102742
235. Z57127551
236. 094caddb-59bf-4edf-b278-59791b203ea2
237. F1908-0167
238. Hydroquinone, Certified Reference Material, Tracecert(r)
239. Hydroquinone, United States Pharmacopeia (usp) Reference Standard
240. Hydroquinone, Pharmaceutical Secondary Standard; Certified Reference Material
| Molecular Weight | 110.11 g/mol |
|---|---|
| Molecular Formula | C6H6O2 |
| XLogP3 | 0.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 0 |
| Exact Mass | 110.036779430 g/mol |
| Monoisotopic Mass | 110.036779430 g/mol |
| Topological Polar Surface Area | 40.5 Ų |
| Heavy Atom Count | 8 |
| Formal Charge | 0 |
| Complexity | 54.9 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the gradual temporary bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation.
Drug Facts and Comparisons 2013. Wolters Kluwer Health St. Louis, MO 2013, p. 3264
TRI-LUMA Cream is a combination of fluocinolone acetonide (a corticosteroid), hydroquinone (a melanin synthesis inhibitor), and tretinoin (a retinoid) that is indicated for the short-term treatment of moderate to severe melasma of the face, in the presence of measures for sun avoidance, including the use of sunscreens. /Included in US product label/
US Natl Inst Health; DailyMed. Current Medication Information for Tri-Luma (fluocinolone acetonide, hydroquinone, and tretinoin) (April 2014). Available from, as of November 12, 2014: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8729
This medication is for external use only. A mild transient stinging may occur in people with sensitive skin. Do not use on broken or irritated skin. Discontinue use if irritation or rush occurs. Avoid contact with eyes and mucous membranes. In case of contact, rinse thoroughly with water.
Drug Facts and Comparisons 2013. Wolters Kluwer Health St. Louis, MO 2013, p. 3265
To evaluate possible susceptibility to irritation, or sensitivity, each patient should begin with applying the medication to a small portion of unbroken skin at or near the pigmented area (approx 1 sq cm) over a period of several days. If no irritation occurs within 24 hr, begin treatment. Minor redness is not necessarily a contraindication, but treatment should be discontinued if itching, excessive inflammation, or vesicle formation occurs. Use of hydroquinone products in paranasal and infraorbital areas increase the chance of irritation. If no improvement is seen after 2 mo of treatment, use of this product should be discontinued.
Drug Facts and Comparisons 2013. Wolters Kluwer Health St. Louis, MO 2013, p. 3265
Sunscreen use is an essential aspect of hydroquinone therapy since even minimal sunlight exposure stimulates melanocyte activity. The sunscreens in some hydroquinone products provide the necessary sun protection during skin bleaching activity. During the depigmentation maintenance treatment subsequent to the intensive depigmentation therapy, sun exposure of the bleached skin should be avoided to prevent repigmentation.
Drug Facts and Comparisons 2013. Wolters Kluwer Health St. Louis, MO 2013, p. 3265
Concurent use of peroxide may result in transient dark staining of skin ares due to oxidation of hydroquinone. Staining can be removed by discontinuing concurrent use and by normal soap cleansing.
Drug Facts and Comparisons 2013. Wolters Kluwer Health St. Louis, MO 2013, p. 3265
For more Drug Warnings (Complete) data for HYDROQUINONE (9 total), please visit the HSDB record page.
Fatal cases have been reported after ingestion of 5 to 12 g.
Clayton, G. D. and F. E. Clayton (eds.). Patty's Industrial Hygiene and Toxicology: Volume 2A, 2B, 2C: Toxicology. 3rd ed. New York: John Wiley Sons, 1981-1982., p. 2591
Hydroquinone is used as an OTC topical lightening agent for disorders of hyperpigmentation including melasma, post-inflammatory hyperpigmention, sunspots and freckles.
FDA Label
Antioxidants
Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. (See all compounds classified as Antioxidants.)
Mutagens
Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes. (See all compounds classified as Mutagens.)
Radiation-Protective Agents
Drugs used to protect against ionizing radiation. They are usually of interest for use in radiation therapy but have been considered for other purposes, e.g. military. (See all compounds classified as Radiation-Protective Agents.)
D - Dermatologicals
D11 - Other dermatological preparations
D11A - Other dermatological preparations
D11AX - Other dermatologicals
D11AX11 - Hydroquinone
A toxicology review of hydroquinone noted several reports indicating relatively rapid absorption of hydroquinone via the oral route, including a study involving rats that ingested 3% hydroquinone in developer solution. In addition, in CD and F344 rats dosed with 350 mg/kg, >90% absorption was measured in blood levels, with peak levels observed within 1 hr.[DHHS/NTP: Nomination Profile Hydroquinone
123-31-9]. Supporting Information for Toxicological Evaluation by the National Toxicology Program. p.10 (2009). Available from, as of November 12, 2014: https://ntp-server.niehs.nih.gov
Following intravenous (iv) administration of radiolabeled hydroquinone, radioactivity (either hydroquinone or a metabolite) was detected within 2 hr in bone marrow and thymus of rats given 1.2-12 mg/kg. Radioactivity was also detected in the liver and bone marrow of these rats up to 24 hr. Whether given in single or repeated oral doses, radioactivity was found in various rat tissues, with the highest concentrations in the liver and kidneys. Following i.v. administration of radiolabeled hydroquinone in dogs, radioactivity was found in the skin, liver, and intestine. When mice were administered 75 mg/kg radiolabeled hydroquinone by intraperitoneal (ip) injection, radioactivity was detected covalently bound to proteins in the liver, kidneys, blood, and bone marrow, with 10-fold higher specific activity in the liver than in the bone marrow...[DHHS/NTP: Nomination Profile Hydroquinone
123-31-9]. Supporting Information for Toxicological Evaluation by the National Toxicology Program. p.12 (2009). Available from, as of November 12, 2014: https://ntp-server.niehs.nih.gov
When 2% [(14)C]-hydroquinone was administered to human forearms (n = 4 males) in an unspecified cream, hydroquinone moved rapidly and continuously into the stratum corneum and radiolabel was detected in plasma samples within 0.5 hr. Over an 8 hr plasma sampling period, hydroquinone levels peaked at 4 hr (0.04 equivalents/ mL). Following application of the 2% cream on the foreheads of 6 male volunteers for 24 hr, the recovery of hydroquinone in urine was 45.3% (SD = 11.2%).[DHHS/NTP: Nomination Profile Hydroquinone
123-31-9]. Supporting Information for Toxicological Evaluation by the National Toxicology Program. p.11 (2009). Available from, as of November 12, 2014: https://ntp-server.niehs.nih.gov
Human absorption of hydroquinone upon topical application is less efficient than with oral administration. When absorption was measured as elimination 10 of hydroquinone via urine following application (2.0% in alcohol) to the foreheads of human volunteers (6 males per preparation) for 24 hr, the average percutaneous absorption reported was 57% (SD = 11%) with peak elimination within 12 hr and complete elimination by 5 days. The addition of a sunscreen (3.0% Escalol 507) significantly decreased the absorption (26%, SD = 14%), and the addition of a penetration enhancer (0.5% Azone) did not significantly increase absorption in the presence or absence of the sunscreen (35%, SD = 17% and 66%, SD = 13%, respectively).[DHHS/NTP: Nomination Profile Hydroquinone
123-31-9]. Supporting Information for Toxicological Evaluation by the National Toxicology Program. p.10-11 (2009). Available from, as of November 12, 2014: https://ntp-server.niehs.nih.gov
For more Absorption, Distribution and Excretion (Complete) data for HYDROQUINONE (17 total), please visit the HSDB record page.
Hydroquinone is absorbed through the skin and metabolized primarily to sulfate and glucuronide conjugates, which are excreted in the urine.[DHHS/NTP: Nomination Profile Hydroquinone
123-31-9]. Supporting Information for Toxicological Evaluation by the National Toxicology Program. p.2 (2009). Available from, as of November 12, 2014: https://ntp-server.niehs.nih.gov
Absolute recovery of approximately 45 ng (18%) of hydroquinone as microsomal metabolite of benzene was determined.
ROSTON DA, KISSINGER PT; ANAL CHEM 54 (11): 1798 (1982)
/This study/ investigated the metabolism of hydroquinone in naive and hydroquinone pretreated male Sprague-Dawley rats. (14)C hydroquinone was administered by gavage in single doses of 5, 30, or 200 mg/kg to naive rats. Hydroquinone was given repeatedly by gavage to male rats at 200 mg/kg for 4 consecutive days followed by a single dose with 200 mg/kg of (14)C hydroquinone. In separate studies rats were fed 5.6% unlabeled hydroquinone in the diet for 2 days or were dosed by gavage with 311 mg/kg (14)C hydroquinone. The excretion patterns of (14)C hydroquinone and its metabolites were similar for rats dosed singly or repeatedly. Rats given a single dose of 200 mg/kg of (14)C hydroquinone excreted 91.9% of the dose in the urine within 2-4 days; 3.8% was excreted in the feces, about 0.4% was excreted in expired air, and 1.2% remained in the carcass. Radioactivity was widely distributed throughout the tissues with higher concentrations in the liver and kidneys. A decrease in (14)C tissue concentrations occurred from 48 to 96 hr. The only radiolabeled compounds in the urine were hydroquinone (1.1-8.6% of the dose), hydroquinone monosulfate (25-42%), and hydroquinone monoglucuronide (56-66%). Similar findings were observed for rats given hydroquinone in the feed. There were no significant increases from controls for absolute or relative liver weights, liver microsomal protein concentrations, cytochrome b-5, cytochrome P450 or cytochrome c reductase activity in rats dosed repeatedly with 200 mg/kg hydroquinone. Cytochrome P450 values were slightly but significantly decreased in rats dosed repeatedly with hydroquinone compared with controls.
Divincenzo GD et al; Toxicol 33 (1): 9-18 (1984)
The metabolite 2-(S-glutathionyl)hydroquinone is formed when a microsomal incubation mixture containing either benzene or phenol is supplemented with glutathione. This metabolite is derived from the conjugation of benzoquinone, an oxidation product of hydroquinone. However, neither the glutathione conjugate or its mercapturate, N-acetyl-S-(2,5-dihydroxyphenyl)-L-cysteine, have been identified as metabolites resulting from in vivo metabolism of benzene, phenol, or hydroquinone. To determine if a hydroxylated mercapturate is produced in vivo, we treated male Sprague-Dawley rats with either benzene (600 mg/kg), phenol (75 mg/kg), or hydroquinone (75 mg/kg) and collected the urine for 24 hr. HPLC coupled with electrochemical detection confirmed the presence of a metabolite that was chromatographically and electrochemically identical to N-acetyl-S-(2,5-dihydroxyphenyl)-L-cysteine. The metabolite was isolated from the urine samples and treated with diazomethane to form the N-acetyl-S-(2,5-dimethoxyphenyl)-L-cysteine methyl ester derivative. The mass spectra obtained from these samples were identical to that of an authentic sample of the derivative. The results of these experiments indicate that benzene, phenol, and hydroquinone are metabolized in vivo to benzoquinone and excreted as the mercapturate, N-acetyl-S-(2,5-dihydroxyphenyl)-L- cysteine.
PMID:1981544 Nerland DE, Pierce WM Jr; Drug Metab Dispos 18 (6): 958-61 (1990)
For more Metabolism/Metabolites (Complete) data for HYDROQUINONE (14 total), please visit the HSDB record page.
Hydroquinone is a known human metabolite of phenol.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
/Hydroquinone was administered alone and in combination with phenol at 75 mg/kg each to B6C3F1 mice/. The half-life of hydroquinone was increased from 9 +/- 2 to 15 +/- 3 min /when phenol was administered in combination with hydroquinone/.
PMID:8291054 Legathe A et al; Toxicol Appl Pharmacol 124 (1): 131-8 (1994)
Hydroquinone reduces melanin pigment production through inhibition of the tyrosinase enzyme, which is involved in the initial step of the melanin pigment biosynthesis pathway. Hydroquinone takes several months to take effect.
Benzene is a well-established human carcinogen. Benzene metabolites hydroquinone (HQ) and benzoquinone (BQ) are highly reactive molecules capable of producing reactive oxygen species and causing oxidative stress. /This study/ investigated the role of the Nrf2, a key nuclear transcription factor that regulates antioxidant response element (ARE)-containing genes, in defense against HQ- and BQ-induced cytotoxicity in cultured human lung epithelial cells (Beas-2B). When the cells were exposed to HQ or BQ the activity of an ARE reporter was induced in a dose-dependent manner, meanwhile Nrf2 protein levels were elevated and accumulated in the nucleus. Increased expression of well-known Nrf2-dependent proteins including NQO1, GCLM, GSS and HMOX was also observed in the HQ/BQ-treated cells. Moreover, transient overexpression of Nrf2 conferred protection against HQ- and BQ-induced cell death, whereas knockdown of Nrf2 by small interfering RNA resulted in increased apoptosis. /This study/ also found that the increased susceptibility of Nrf2-knockdown cells to HQ and BQ was associated with reduced glutathione levels and loss of inducibility of ARE-driven genes, suggesting that deficiency of Nrf2 impairs cellular redox capacity to counteract oxidative damage. Altogether, these results suggest that Nrf2-ARE pathway is essential for protection against HQ- and BQ-induced toxicity.
PMID:21059386 Rubio V et al; Toxicol In Vitro. 25(2):521-9. (2011).
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
EUROAPI
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Minakem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharm-RX Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kewpie Corporation
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Bioplus Life Sciences
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CD Formulation
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Esteem Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lubrizol Life Science Health
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Bold Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shandong Focus Biotechnology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Topical
Thickeners and Stabilizers
Solubilizers
Parenteral
Emulsifying Agents
Surfactant & Foaming Agents
Film Formers & Plasticizers
Coating Systems & Additives
Rheology Modifiers
Lubricants & Glidants
Fillers, Diluents & Binders
Controlled & Modified Release
Granulation
Taste Masking
Direct Compression
API Stability Enhancers
Co-Processed Excipients
Coloring Agents
Disintegrants & Superdisintegrants
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
Analytical Methods
ABOUT THIS PAGE
98
PharmaCompass offers a list of Hydroquinone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Hydroquinone manufacturer or Hydroquinone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Hydroquinone manufacturer or Hydroquinone supplier.
PharmaCompass also assists you with knowing the Hydroquinone API Price utilized in the formulation of products. Hydroquinone API Price is not always fixed or binding as the Hydroquinone Price is obtained through a variety of data sources. The Hydroquinone Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Eldoquin Forte manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Eldoquin Forte, including repackagers and relabelers. The FDA regulates Eldoquin Forte manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Eldoquin Forte API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Eldoquin Forte manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Eldoquin Forte supplier is an individual or a company that provides Eldoquin Forte active pharmaceutical ingredient (API) or Eldoquin Forte finished formulations upon request. The Eldoquin Forte suppliers may include Eldoquin Forte API manufacturers, exporters, distributors and traders.
click here to find a list of Eldoquin Forte suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Eldoquin Forte DMF (Drug Master File) is a document detailing the whole manufacturing process of Eldoquin Forte active pharmaceutical ingredient (API) in detail. Different forms of Eldoquin Forte DMFs exist exist since differing nations have different regulations, such as Eldoquin Forte USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Eldoquin Forte DMF submitted to regulatory agencies in the US is known as a USDMF. Eldoquin Forte USDMF includes data on Eldoquin Forte's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Eldoquin Forte USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Eldoquin Forte suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Eldoquin Forte Drug Master File in Korea (Eldoquin Forte KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Eldoquin Forte. The MFDS reviews the Eldoquin Forte KDMF as part of the drug registration process and uses the information provided in the Eldoquin Forte KDMF to evaluate the safety and efficacy of the drug.
After submitting a Eldoquin Forte KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Eldoquin Forte API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Eldoquin Forte suppliers with KDMF on PharmaCompass.
A Eldoquin Forte written confirmation (Eldoquin Forte WC) is an official document issued by a regulatory agency to a Eldoquin Forte manufacturer, verifying that the manufacturing facility of a Eldoquin Forte active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Eldoquin Forte APIs or Eldoquin Forte finished pharmaceutical products to another nation, regulatory agencies frequently require a Eldoquin Forte WC (written confirmation) as part of the regulatory process.
click here to find a list of Eldoquin Forte suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Eldoquin Forte as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Eldoquin Forte API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Eldoquin Forte as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Eldoquin Forte and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Eldoquin Forte NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Eldoquin Forte suppliers with NDC on PharmaCompass.
Eldoquin Forte Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Eldoquin Forte GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Eldoquin Forte GMP manufacturer or Eldoquin Forte GMP API supplier for your needs.
A Eldoquin Forte CoA (Certificate of Analysis) is a formal document that attests to Eldoquin Forte's compliance with Eldoquin Forte specifications and serves as a tool for batch-level quality control.
Eldoquin Forte CoA mostly includes findings from lab analyses of a specific batch. For each Eldoquin Forte CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Eldoquin Forte may be tested according to a variety of international standards, such as European Pharmacopoeia (Eldoquin Forte EP), Eldoquin Forte JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Eldoquin Forte USP).
